- Home
- ANAB vs LAC Comparison
ANAB vs LAC Comparison
Compare ANAB & LAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- LAC
- Stock Information
- Founded
- ANAB 2005
- LAC 2023
- Country
- ANAB United States
- LAC Canada
- Employees
- ANAB N/A
- LAC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- LAC Metal Mining
- Sector
- ANAB Health Care
- LAC Basic Materials
- Exchange
- ANAB Nasdaq
- LAC Nasdaq
- Market Cap
- ANAB 759.5M
- LAC 666.1M
- IPO Year
- ANAB 2017
- LAC N/A
- Fundamental
- Price
- ANAB $18.59
- LAC $2.72
- Analyst Decision
- ANAB Buy
- LAC Hold
- Analyst Count
- ANAB 10
- LAC 7
- Target Price
- ANAB $36.38
- LAC $4.41
- AVG Volume (30 Days)
- ANAB 892.6K
- LAC 4.5M
- Earning Date
- ANAB 05-08-2025
- LAC 05-12-2025
- Dividend Yield
- ANAB N/A
- LAC N/A
- EPS Growth
- ANAB N/A
- LAC N/A
- EPS
- ANAB N/A
- LAC N/A
- Revenue
- ANAB $91,280,000.00
- LAC N/A
- Revenue This Year
- ANAB N/A
- LAC N/A
- Revenue Next Year
- ANAB $59.43
- LAC N/A
- P/E Ratio
- ANAB N/A
- LAC N/A
- Revenue Growth
- ANAB 432.03
- LAC N/A
- 52 Week Low
- ANAB $12.21
- LAC $2.02
- 52 Week High
- ANAB $41.31
- LAC $7.71
- Technical
- Relative Strength Index (RSI)
- ANAB 57.06
- LAC 40.76
- Support Level
- ANAB $17.50
- LAC $2.92
- Resistance Level
- ANAB $19.60
- LAC $3.10
- Average True Range (ATR)
- ANAB 1.37
- LAC 0.13
- MACD
- ANAB 0.20
- LAC -0.02
- Stochastic Oscillator
- ANAB 60.56
- LAC 24.24
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, that is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass recently began construction and is expected to begin production in the mid- to late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.